Who holds the certolizumab pegol (Cimzia) patents, and does UCB still control them?
Certolizumab pegol (marketed as Cimzia) is developed and marketed by UCB. Patent rights are held through a set of national and regional filings that can be owned by UCB companies and related entities rather than one single “UCB patent” worldwide. What matters for users and competitors is the status in each country (granted patents, expirations, and any extensions) rather than a single global deadline.
When do Cimzia/certolizumab pegol patents expire?
Patent expiry depends on the jurisdiction and the specific patent family (not all patents in a product portfolio expire on the same date). Key dates often include:
- the “basic” patent expiry for the relevant claims, and
- any regulatory or patent-term extensions that apply in a country.
Because expiry is country- and claim-specific, the most accurate answer requires looking up the patent family for the exact indication and territory (for example, EU vs. US vs. UK) and identifying which claims are still in force.
What does this mean for biosimilars or competition to Cimzia?
If you are looking for when biosimilars could enter, the practical limiter is whether key certolizumab pegol patents (and any extended protection) are still active in the target market. Even if one patent expires, other “evergreening” patents can delay entry until their protection ends.
How to check the patent situation quickly for a specific country
For the most relevant answer to “UCB patent certolizumab pegol,” you typically need three inputs:
1) the target country (or region),
2) whether you care about the original product or specific manufacturing/formulation/process claims, and
3) the indication (patent landscapes can differ by claim scope).
You then check the in-force status in that jurisdiction using patent databases (national patent registers or tools that consolidate them).
What I need from you to give a precise UCB patent/expiry answer
“Certolizumab pegol patent ucb” can’t be pinned to one expiration date without territory. Tell me:
- which country/region you mean (US, EU, UK, etc.), and
- whether you want general expiry or the date tied to biosimilar entry.
If you share that, I can outline what the key certolizumab pegol patent families cover (as far as the provided info allows) and how the timing affects competition.
Sources
I don’t have any patent- or expiry-specific sources in the provided information, so I can’t cite them reliably here.